Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norovirus GII.4 Challenge Dose Finding
NCT02337842Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2015
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of subjects experiencing any mild, moderate or severe reactogenicity outcomes, Proportion of subjects with Norovirus-GII.4 Challenge Stock associated illness and 3 more. Planned start Sep 2015; status: withdrawn.
Beyond the preview
Go deeper on NCT02337842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337842.